Second cite.
Friedmann
P S
PS
psf@soton.ac.uk
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000252:Calcium-Transporting ATPases / Q000235:genetics; D007644:Darier Disease / Q000235:genetics; D005192:Family Health; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007509:Irritants / Q000009:adverse effects; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000556:secondary*; D009154:Mutation; D009456:Neurofibromatosis 1 / Q000235:genetics*; D010392:Pemphigus / Q000188:drug therapy*; D016506:Pemphigus, Benign Familial / Q000235:genetics; D010539:Permeability; D010641:Phenotype; D000069283:Rituximab; D012867:Skin / Q000187:drug effects; D012878:Skin Neoplasms; D012915:Soaps / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007509:Irritants; D012915:Soaps; D000069283:Rituximab; D000252:Calcium-Transporting ATPases